New triple therapy could simplify h. pylori treatment

NCT ID NCT07358130

Recruiting now Disease control Sponsor: Kaohsiung Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two 14-day antibiotic treatments for Helicobacter pylori infection, a common stomach bug that can cause ulcers. The triple therapy uses bismuth, amoxicillin, and vonoprazan, while the quadruple therapy adds rabeprazole, tetracycline, and metronidazole. Researchers will check which treatment works better and is safer in 552 infected adults, and also look at how antibiotic resistance and genetics affect success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vonoprazan, bismuth, amoxicillin, rabeprazole, tetracycline, metronidazole
What this could lead to: If successful, this could show that a simpler triple therapy works as well as the standard quadruple therapy for treating H. pylori infection.
What could go wrong: This is a single-site trial with 552 participants, so results may not apply to everyone. Antibiotic resistance could reduce effectiveness, and side effects like stomach upset are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HELICOBACTER PYLORI INFECTION

Contacts and locations

Locations

Kaohsiung Medical University Hospital
RECRUITING

Kaohsiung City, 807, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.